Bullish
Pfizer's stock approaches 52-week high after solid Q2 earnings report.
Pfizer Inc. (NYSE: PFE) reported strong second-quarter 2026 results, with revenues of $15.03 billion, a 2.6% increase from the previous year, surpassing analyst expectations. The company's stock is trading near its 52-week high, reflecting investor confidence.
Key points
- Pfizer's Q2 2026 revenue of $15.03 billion exceeded expectations, marking a 2.6% year-over-year increase.
- Analysts maintain a 'Hold' rating on Pfizer, with an average 12-month price target of $28.28.
- Institutional investors are adjusting their positions; ADAR1 Capital Management LLC increased its holdings by 226.1%, while Legal & General Group Plc reduced its stake by 0.6%.
Sources
- Die Pfizer-Aktie nähert sich dem 52-Wochen-Hoch nach soliden Q2-ZahlenAD HOC NEWS · August 26, 2026
- Pfizer Inc. (NYSE:PFE) Given Average Rating of 'Hold' by BrokeragesMarketBeat · August 26, 2026
- ADAR1 Capital Management LLC Purchases 175,000 Shares of Pfizer Inc. $PFEDefense World · August 26, 2026
- Legal & General Group Plc Lowers Holdings in Pfizer Inc. $PFEMarketBeat · August 26, 2026
AI-generated from public news sources. Not financial advice.
